$RARE

Horn Howard (Chief Financial Officer) sold 7,066 shares of Ultragenyx Pharmaceutical Inc. (RARE) at $15.27 ($0.11M total) on 2026-10-15.

Ultragenyx settled patent litigation with Navinta, allowing a generic version of DOJOLVI to launch from Jan 1, 2033. The license may extend to July 1, 2033 if pediatric exclusivity is granted. Other DOJOLVI-related patent suits are still pending.

Ultragenyx Pharmaceutical Inc. (RARE) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 19, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) and Baylor Research Institute (“BRI”) entered into a settlement agreement with Navinta LLC (“Navinta”) resolving patent litigation related to patents covering the Company’s DOJOLVI® (trihe

Ultragenyx Pharmaceutical Inc. (RARE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 8, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) entered into an asset purchase agreement (the “PRV Asset Purchase Agreement”), pursuant to which the Company agreed to sell a Rare Pediatric Disease Priority R

Ultragenyx Pharmaceutical Inc. (RARE) announced a $203 million deal to sell a Rare Pediatric Disease Priority Review Voucher (PRV). This is the company's second PRV sale in a week, with proceeds aimed at funding innovative treatments and supporting profitability. The transaction is subject to customary closing conditions, including antitrust review. Jefferies LLC and Gibson, Dunn and Crutcher LLP are advising Ultragenyx on the deal.

Revolution Medicines' shares fell 6% after FDA documents suggested its pancreatic cancer drug Rasonque may be less effective in certain patients. Zealand Pharma's petrelintide showed weight loss and blood sugar reductions in a Phase 2 trial, but analysts found the blood sugar results underwhelming. Pfizer's Tukysa gained FDA approval for frontline breast cancer treatment. Ultragenyx sold a regulatory voucher for $210M, strengthening its balance sheet.

Ultragenyx Pharmaceutical (RARE) announced that the European Medicines Agency (EMA) has validated its Marketing Authorisation Application for rebisufligene etisparvovec, a gene therapy for Sanfilippo syndrome Type A. This validation confirms the filing is complete for review but does not guarantee approval. The company reported a US$115 million loss in Q2 2025 and has a cash runway of less than one year.

FuelCell Energy (FCEL) shares dropped 15% after announcing a CFO transition. Ondas (ONDS) fell 5% despite $165M in new orders. Ultragenyx (RARE) rose 3.2% after selling a priority review voucher for $210M. TNR Gold (TNR) received an acquisition proposal from Altius (ALS). Rocket Pharma (RCKT) gained 4% after securing a $150M credit facility. Sigma Lithium (SGML) resumed operations after court approval. Hess Midstream (HESM) fell 16% after Chevron deal.

Ultragenyx Pharmaceutical Inc. (RARE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 6, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) entered into an asset purchase agreement (the “PRV Asset Purchase Agreement”), pursuant to which the Company agreed to sell a Rare Pediatric Disease Priority R

Ultragenyx Pharmaceutical (RARE) agreed to sell a Rare Pediatric Disease Priority Review Voucher for $210M. The voucher was received after FDA approval of GENGLYCOS, a treatment for glycogen storage disease type Ia. The deal, subject to closing conditions, will provide non-dilutive capital to advance rare disease therapies and support profitability. Jefferies LLC and Gibson Dunn are advising Ultragenyx.